Create account

Coverage dated November 8, 2026 to November 11, 2026

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

Headline from STAT, on the newest of 2 developments

The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

STAT's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Developments in this update

2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.

  1. FDA requires safety label changes for GLP-1s over risk for eye condition

    Headline from KXAN Austin ·

  2. Newest

    STAT+: GLP-1s are given an FDA warning for rare eye condition risk

    Headline from STAT ·

4 reports not tied to one development ·

Read the reports

Reports & sources

32 articles, oldest first.

  1. NBC 5 Dallas-Fort Worth

    FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness (opens NBC 5 Dallas-Fort Worth)

    Published

    NBC 5 Dallas-Fort Worth's feed description

    Syringe needle drops medication beside GLP-1 vial offering hopeful medical weight loss injection therapy for clinical diabetes care. Getty Images/ iStockphoto

  2. STAT

    STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition (opens STAT)

    Published

    STAT's feed description

    The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."

  3. The Boston Globe

    FDA warns GLP-1 drugs carry potential risk of rare eye condition (opens The Boston Globe)

    Published

    The Boston Globe's feed description

    The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes referred to as an “eye stroke.”

  4. News Nation Now

    FDA requires safety label changes for GLP-1s over risk for eye condition (opens News Nation Now)

    Published

    News Nation Now's feed description

    NAION is often called an “eye stroke” because it occurs when blood flow to the optic nerve is reduced.

  5. Townhall

    FDA Now Requiring GLP-1 Makers to Warn About Rare but Severe Eye Condition (opens Townhall)

    Published

  6. MLive

    Ozempic, Wegovy and Zepbound get new FDA warning over rare condition (opens MLive)

    Published

    MLive's feed description

    The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision loss.

  7. STAT

    STAT+: GLP-1s are given an FDA warning for rare eye condition risk (opens STAT)

    Published

    STAT's feed description

    The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

  8. The Conversation US

    GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect (opens The Conversation US)

    Published

    The Conversation US's feed description

    Doctors often call the condition a stroke of the eye – and though the risk is small, patients should know the symptoms and seek immediate treatment if they occur.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

STAT+: GLP-1s are given an FDA warning for rare eye condition risk | Since Then